Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy

Abstract

Conflicts of Interest and Source of FundingMF received speakers' honoraria and support for travel to meetings from Bristol-Myers Squibb (BMS), Gilead, Janssen-Cilag, Merck Sharp & Dohme (MSD), ViiV Healtcare, and fees for attending advisory boards from BMS, Gilead and Janssen-Cilag. AB received speaker's honoraria from Janssen-Cilag and fees for attending an advisory board from Viiv Healthcare. NS received a grant for advisor from ViiV and travel grants and speaker's honoraria from Gilead and Janssen. MC declares personal fees from Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme, ViiV Healthcare, and Bristol-Myers Squibb, outside the submitted work. LT received fees for attending advisory boards from Janssen-Cilag and ViiV Healtcare and support for travel to meetings from Gilead, Janssen-Cilag, Merck Sharp & Dohme (MSD). BR received speakers' honoraria and support for travel to meetings from Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme (MSD), ViiV Healthcare, and fees for attending advisory boards from ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme (MSD), Gilead Sciences, Bristol-Myers Squibb (BMS). AC received travel grants from ViiV Healthcare. ADB received speakers' honoraria and support for travel to meetings

Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort

“…This is mainly due to their efficacy and improved tolerability with respect to older drug classes; in particular, a rapid viral decay has been observed in patients treated with InSTIs, with lower impact on lipid profile, improved gastrointestinal tolerability, and good renal, hepatic and bone safety [3]. Moreover, recent reports seem also to suggest a benefit of InSTIs in terms of immunological recovery when in comparison to protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors [4]. Indeed, a more convenient inflammatory profile has been observed in patients switched to InSTIs [5][6][7].…”

B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy

“…Among them, 57 (67.9%) had >500 CD4+ T cells/µl (High CD4+), 13 (15.5%) were in the 350-500 CD4+ T cells/µl range (Average CD4+) and 14 (16.7%) had values <350 CD4+ T cells/µl (Low CD4+). At baseline, 28 (33.3%) PLWHIV showed optimal immunological recovery, defined as CD4+ T cells count ≥500 cell/µl plus CD4+ T cells % ≥ 30% plus CD4/CD8 ratio ≥ 1 (22,23). Clinical and demographic data of PLWHIV cohorts were collected before the first dose for the statistical analysis and reported in Supplementary table 1.…”

CD4+ T lymphocyte recovery in the modern antiretroviral therapy era: Toward a new threshold for defining immunological non-responders

“…The higher frequency of INR 200 found in previous years might reflect the use of older drugs that are currently considered sub-optimal or less tolerable, possibly compromising overall ART efficacy and, consequently, also immunological recovery (11,42,44). On the contrary, newer drugs such as INSTIs (46,47), and also PIs, when compared with older ART approaches (48), might favor a more effective immune recovery. However, in our study, we did not find a consistent correlation between INR rate and months of exposure to different classes of antiretrovirals.…”